- Home
- GOSS vs DFDV Comparison
GOSS vs DFDV Comparison
Compare GOSS & DFDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- DFDV
- Stock Information
- Founded
- GOSS 2015
- DFDV 2018
- Country
- GOSS United States
- DFDV United States
- Employees
- GOSS N/A
- DFDV N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- DFDV Finance: Consumer Services
- Sector
- GOSS Health Care
- DFDV Finance
- Exchange
- GOSS Nasdaq
- DFDV Nasdaq
- Market Cap
- GOSS 347.8M
- DFDV 330.2M
- IPO Year
- GOSS 2019
- DFDV N/A
- Fundamental
- Price
- GOSS $2.47
- DFDV $16.02
- Analyst Decision
- GOSS Strong Buy
- DFDV Buy
- Analyst Count
- GOSS 4
- DFDV 1
- Target Price
- GOSS $8.50
- DFDV $45.00
- AVG Volume (30 Days)
- GOSS 3.1M
- DFDV 3.5M
- Earning Date
- GOSS 08-05-2025
- DFDV 08-12-2025
- Dividend Yield
- GOSS N/A
- DFDV N/A
- EPS Growth
- GOSS N/A
- DFDV N/A
- EPS
- GOSS N/A
- DFDV 1.17
- Revenue
- GOSS $40,237,000.00
- DFDV $3,520,660.00
- Revenue This Year
- GOSS N/A
- DFDV $70.03
- Revenue Next Year
- GOSS $30.65
- DFDV $142.86
- P/E Ratio
- GOSS N/A
- DFDV $13.67
- Revenue Growth
- GOSS N/A
- DFDV 97.13
- 52 Week Low
- GOSS $0.66
- DFDV $0.49
- 52 Week High
- GOSS $2.65
- DFDV $53.88
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- DFDV 46.25
- Support Level
- GOSS $2.38
- DFDV $15.23
- Resistance Level
- GOSS $2.65
- DFDV $20.30
- Average True Range (ATR)
- GOSS 0.15
- DFDV 2.30
- MACD
- GOSS 0.03
- DFDV 0.08
- Stochastic Oscillator
- GOSS 76.67
- DFDV 19.72
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.